Actinogen Medical Advances Alzheimer’s and Depression Trials with Regulatory and Manufacturing Milestones

The latest announcement is out from Actinogen Medical ( (AU:ACW) ).

Actinogen Medical has made significant progress in its XanaMIA phase 2b/3 clinical trial for Alzheimer’s disease, with accelerated patient screening and enrollment across multiple sites in the US and Australia. The company also achieved a successful regulatory meeting with the FDA regarding major depressive disorder, marking a major accomplishment that could enhance future partnerships and funding opportunities. Additionally, the World Health Organization granted a unique name to Xanamem, recognizing its novel mechanism of action, and the company continues to advance its manufacturing and strategic planning efforts.

More about Actinogen Medical

Actinogen Medical is a biotechnology company focused on developing treatments for central nervous system diseases. Their primary product is Xanamem, an orally administered drug designed to control toxic cortisol levels in the brain, targeting conditions such as Alzheimer’s disease and major depressive disorder.

YTD Price Performance: 25.00%

Average Trading Volume: 75,000

Technical Sentiment Signal: Sell

Current Market Cap: $55.14M

For an in-depth examination of ACW stock, go to TipRanks’ Stock Analysis page.